BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 20971146)

  • 1. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
    Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloantibodies in heart transplantation.
    Ho EK; Vlad G; Colovai AI; Vasilescu ER; Schwartz J; Sondermeijer H; Burke E; Marboe CC; Itescu S; Suciu-Foca N; Mancini D
    Hum Immunol; 2009 Oct; 70(10):825-9. PubMed ID: 19555730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloantibodies and the outcome of cadaver kidney allografts.
    Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N
    Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
    Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
    Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-mediated rejection: treatment alternatives and outcomes.
    Singh N; Pirsch J; Samaniego M
    Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation.
    Caro-Oleas JL; González-Escribano MF; Gentil-Govantes MÁ; Acevedo MJ; González-Roncero FM; Blanco GB; Núñez-Roldán A
    Transplantation; 2012 Aug; 94(4):338-44. PubMed ID: 22814330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period.
    Sánchez-Zapardiel E; Castro-Panete MJ; Castillo-Rama M; Morales P; Lora-Pablos D; Valero-Hervás D; Ruiz-García R; Apaza J; Talayero P; Andrés A; Morales JM; Paz-Artal E
    Transplantation; 2013 Jul; 96(1):70-8. PubMed ID: 23624543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased anti-donor major histocompatibility complex class I and increased class II alloantibody response in allograft tolerance in adult rats.
    Cuturi MC; Josien R; Cantarovich D; Bugeon L; Anegon I; Menoret S; Smit H; Douillard P; Soulillou JP
    Eur J Immunol; 1994 Jul; 24(7):1627-31. PubMed ID: 8026523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss.
    Lee PC; Zhu L; Terasaki PI; Everly MJ
    Transplantation; 2009 Aug; 88(4):568-74. PubMed ID: 19696641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.